We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Blue Stream Laboratories Adds Capacity
News

Blue Stream Laboratories Adds Capacity

Blue Stream Laboratories Adds Capacity
News

Blue Stream Laboratories Adds Capacity

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Blue Stream Laboratories Adds Capacity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Blue Stream Laboratories is expanding into new office and lab space, adjacent to its current facility, to handle the continued growth of its biosimilars services. Last year, the company moved into new space in Woburn to double the capacity of its prior Cambridge facility.

Blue Stream will exhibit at Booth 8 at the Well Characterized Biologicals Conference from Nov. 9-10 at the Hyatt Regency Reston VA.

Having provided characterization services for 10 of the top biosimilar products in development, Blue Stream offers a complete suite of analytical solutions for biosimilar product development from initial product screening to biosimilar/originator comparability to comprehensive characterization including primary and secondary/tertiary structure, glycosylation/PTMs, and activity.

The biosimilar segment continues to perform well for the company. In 2014, Blue Stream recorded a 60 percent increase in revenue over the prior year, along with a 50 percent increase in facility size, and a 30 percent expansion of its research and development capabilities. This growth was significantly driven by Blue Stream’s biosimilars services.

“The market for biosimilars continues to grow, with consensus of reaching at least $20 billion within the next few years. Blue Stream has significant biosimilar expertise, and we continue to invest in the people, equipment and infrastructure to develop innovative methods, improve quality and extend our expertise,” said William Rash, VP, Sales and Marketing of Blue Stream Laboratories.

Advertisement